Citadel Advisors’s Integra LifeSciences IART Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-2,300
| Closed | -$50.6K | – | 13646 |
|
|
2025
Q1 | $50.6K | Sell |
2,300
-12,900
| -85% | -$303K | ﹤0.01% | 12302 |
|
|
2024
Q4 | $345K | Buy |
15,200
+5,000
| +49% | +$109K | ﹤0.01% | 9368 |
|
|
2024
Q3 | $185K | Buy |
10,200
+6,000
| +143% | +$139K | ﹤0.01% | 10266 |
|
|
2024
Q2 | $122K | Buy |
4,200
+1,600
| +62% | +$47.5K | ﹤0.01% | 10631 |
|
|
2024
Q1 | $92.2K | Buy |
+2,600
| New | +$104K | ﹤0.01% | 11466 |
|
|
2023
Q3 | – | Sell |
-2,200
| Closed | -$90.5K | – | 14639 |
|
|
2023
Q2 | $90.5K | Hold |
2,200
| – | – | ﹤0.01% | 11074 |
|
|
2023
Q1 | $126K | Sell |
2,200
-20,900
| -90% | -$1.18M | ﹤0.01% | 10917 |
|
|
2022
Q4 | $1.3M | Buy |
23,100
+16,800
| +267% | +$855K | ﹤0.01% | 6316 |
|
|
2022
Q3 | $267K | Buy |
+6,300
| New | +$323K | ﹤0.01% | 9823 |
|
|
2022
Q1 | – | Sell |
-8,000
| Closed | -$536K | – | 14016 |
|
|
2021
Q4 | $536K | Buy |
+8,000
| New | +$541K | ﹤0.01% | 9530 |
|
|
2021
Q1 | – | Sell |
-4,200
| Closed | -$273K | – | 13412 |
|
|
2020
Q4 | $273K | Buy |
+4,200
| New | +$226K | ﹤0.01% | 9233 |
|
|
2019
Q2 | – | Sell |
-8,200
| Closed | -$457K | – | 9467 |
|
|
2019
Q1 | $457K | Buy |
8,200
+2,900
| +55% | +$148K | ﹤0.01% | 6937 |
|
|
2018
Q4 | $239K | Buy |
5,300
+1,600
| +43% | +$87.8K | ﹤0.01% | 7614 |
|
|
2018
Q3 | $244K | Buy |
+3,700
| New | +$230K | ﹤0.01% | 7913 |
|
|
2016
Q4 | – | Sell |
-5,400
| Closed | -$223K | – | 7504 |
|
|
2016
Q3 | $223K | Buy |
+5,400
| New | +$226K | ﹤0.01% | 6155 |
|
|
2016
Q1 | – | Sell |
-2,200
| Closed | -$75K | – | 7290 |
|
|
2015
Q4 | $75K | Sell |
2,200
-2,400
| -52% | -$75K | ﹤0.01% | 6967 |
|
|
2015
Q3 | $137K | Buy |
4,600
+1,664
| +57% | +$52K | ﹤0.01% | 6612 |
|
|
2015
Q2 | $81K | Sell |
2,936
-2,936
| -50% | -$78.2K | ﹤0.01% | 7289 |
|
|
2015
Q1 | $148K | Buy |
+5,872
| New | +$139K | ﹤0.01% | 6498 |
|
|
2014
Q4 | – | Sell |
-5,382
| Closed | -$109K | – | 8588 |
|
|
2014
Q3 | $109K | Sell |
5,382
-979
| -15% | -$19.5K | ﹤0.01% | 6322 |
|
|
2014
Q2 | $122K | Buy |
6,361
+3,670
| +136% | +$68.4K | ﹤0.01% | 6064 |
|
|
2014
Q1 | $51K | Hold |
2,691
| – | – | ﹤0.01% | 6768 |
|
|
2013
Q4 | $52K | Sell |
2,691
-2,202
| -45% | -$40.4K | ﹤0.01% | 6010 |
|
|
2013
Q3 | $81K | Buy |
4,893
+2,447
| +100% | +$39.3K | ﹤0.01% | 5483 |
|
|
2013
Q2 | $37K | Buy |
+2,446
| New | +$35.8K | ﹤0.01% | 5805 |
|
Other funds holding IART
RCMNY
PCMI
Citadel Advisors's IART Position: Q2 2026 in Review
Citadel Advisors sold out of Integra LifeSciences (IART) in Q2 2026, closing a stake of 476,701 shares — an estimated $4.49M sold.
Citadel Advisors first reported a position in IART in Q2 2013 and held it in 42 quarters. The position peaked at $22.7M in Q1 2017. 212 funds tracked by Wall St. Rank hold IART as of Q2 2026.
- Citadel Advisors reported no remaining Integra LifeSciences position as of Q2 2026 after selling out during the quarter.
- Citadel Advisors sold 476,701 Integra LifeSciences shares in Q2 2026, an estimated $4.49M.
- Citadel Advisors first reported a position in Integra LifeSciences in Q2 2013 and held it in 42 quarters.
- Citadel Advisors's Integra LifeSciences position peaked at $22.7M in Q1 2017.
- 212 funds tracked by Wall St. Rank held Integra LifeSciences as of Q2 2026.
Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.